Assessment Status | Rapid Review Complete |
HTA ID | 23017 |
Drug | Relugolix |
Brand | Orgovyx® |
Indication | Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. |
Assessment Process | |
Rapid review commissioned | 14/03/2023 |
Rapid review completed | 31/03/2023 |
Rapid review outcome | A full HTA is not recommended. The NCPE recommends that relugolix not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.